➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Harvard Business School
Merck
McKesson
Colorcon

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Nimotuzumab


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Nimotuzumab?

Nimotuzumab is an investigational drug.

There have been 72 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Squamous Cell, and Esophageal Neoplasms. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Peking University, and Sun Yat-sen University.

There are seventy-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Nimotuzumab
TitleSponsorPhase
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell CarcinomaXin-Hua XuPhase 2
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)University of SaskatchewanPhase 1/Phase 2
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal CarcinomaSun Yat-sen UniversityPhase 2

See all Nimotuzumab clinical trials

Clinical Trial Summary for Nimotuzumab

Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab

See all Nimotuzumab clinical trials

US Patents for Nimotuzumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nimotuzumab   Start Trial Binding molecules specific for HER3 and uses thereof MEDIMMUNE, LLC (Gaithersburg, MD)   Start Trial
Nimotuzumab   Start Trial Multispecific constructs AbbVie Stemcentrx LLC (North Chicago, IL)   Start Trial
Nimotuzumab   Start Trial Anti-EGFR activatable antibodies CytomX Therapeutics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Johnson and Johnson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.